These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 20959811)
21. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Croyle MA; Chirmule N; Zhang Y; Wilson JM Hum Gene Ther; 2002 Oct; 13(15):1887-900. PubMed ID: 12396620 [TBL] [Abstract][Full Text] [Related]
22. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides. Espenlaub S; Wortmann A; Engler T; Corjon S; Kochanek S; Kreppel F J Gene Med; 2008 Dec; 10(12):1303-14. PubMed ID: 18837065 [TBL] [Abstract][Full Text] [Related]
23. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Campos SK; Barry MA Virology; 2006 Jun; 349(2):453-62. PubMed ID: 16504233 [TBL] [Abstract][Full Text] [Related]
24. Surface Modification of Adenovirus Vector to Improve Immunogenicity and Tropism. Gabal Y; Ramsey JD Methods Mol Biol; 2021; 2183():357-366. PubMed ID: 32959253 [TBL] [Abstract][Full Text] [Related]
25. Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo. Prill JM; Subr V; Pasquarelli N; Engler T; Hoffmeister A; Kochanek S; Ulbrich K; Kreppel F PLoS One; 2014; 9(1):e82716. PubMed ID: 24475024 [TBL] [Abstract][Full Text] [Related]
26. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Waddington SN; Parker AL; Havenga M; Nicklin SA; Buckley SM; McVey JH; Baker AH J Virol; 2007 Sep; 81(17):9568-71. PubMed ID: 17553882 [TBL] [Abstract][Full Text] [Related]
27. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Liu Q; Zaiss AK; Colarusso P; Patel K; Haljan G; Wickham TJ; Muruve DA Hum Gene Ther; 2003 May; 14(7):627-43. PubMed ID: 12804145 [TBL] [Abstract][Full Text] [Related]
28. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. Koizumi N; Mizuguchi H; Sakurai F; Yamaguchi T; Watanabe Y; Hayakawa T J Virol; 2003 Dec; 77(24):13062-72. PubMed ID: 14645563 [TBL] [Abstract][Full Text] [Related]
29. Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Smith JS; Xu Z; Tian J; Stevenson SC; Byrnes AP Hum Gene Ther; 2008 May; 19(5):547-54. PubMed ID: 18447633 [TBL] [Abstract][Full Text] [Related]
30. Modification of pIX or hexon based on fiberless Ad vectors is not effective for targeted Ad vectors. Kurachi S; Koizumi N; Tashiro K; Sakurai H; Sakurai F; Kawabata K; Nakagawa S; Mizuguchi H J Control Release; 2008 Apr; 127(1):88-95. PubMed ID: 18258327 [TBL] [Abstract][Full Text] [Related]
31. Transcellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitro. Laakkonen JP; Engler T; Romero IA; Weksler B; Couraud PO; Kreppel F; Kochanek S PLoS One; 2012; 7(9):e45977. PubMed ID: 23029348 [TBL] [Abstract][Full Text] [Related]
32. Adenovirus de-targeting from the liver. Di Paolo NC; Shayakhmetov DM Curr Opin Mol Ther; 2009 Oct; 11(5):523-31. PubMed ID: 19806500 [TBL] [Abstract][Full Text] [Related]
33. Pharmacological interventions for improving adenovirus usage in gene therapy. Haisma HJ; Bellu AR Mol Pharm; 2011 Feb; 8(1):50-5. PubMed ID: 20979428 [TBL] [Abstract][Full Text] [Related]
35. Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. Lenaerts L; McVey JH; Baker AH; Denby L; Nicklin S; Verbeken E; Naesens L J Gene Med; 2009 Feb; 11(2):119-27. PubMed ID: 19065608 [TBL] [Abstract][Full Text] [Related]
36. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Alba R; Bradshaw AC; Parker AL; Bhella D; Waddington SN; Nicklin SA; van Rooijen N; Custers J; Goudsmit J; Barouch DH; McVey JH; Baker AH Blood; 2009 Jul; 114(5):965-71. PubMed ID: 19429866 [TBL] [Abstract][Full Text] [Related]
37. Two key challenges for effective adenovirus-mediated liver gene therapy: innate immune responses and hepatocyte-specific transduction. Descamps D; Benihoud K Curr Gene Ther; 2009 Apr; 9(2):115-27. PubMed ID: 19355869 [TBL] [Abstract][Full Text] [Related]
38. Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer. Snoeys J; Mertens G; Lievens J; van Berkel T; Collen D; Biessen EA; De Geest B Mol Ther; 2006 Jan; 13(1):98-107. PubMed ID: 16112619 [TBL] [Abstract][Full Text] [Related]
39. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. Bayo-Puxan N; Cascallo M; Gros A; Huch M; Fillat C; Alemany R J Gen Virol; 2006 Sep; 87(Pt 9):2487-2495. PubMed ID: 16894186 [TBL] [Abstract][Full Text] [Related]
40. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. Bradshaw AC; Coughlan L; Miller AM; Alba R; van Rooijen N; Nicklin SA; Baker AH J Control Release; 2012 Dec; 164(3):394-402. PubMed ID: 22626939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]